CPIG
ADAP

Chicago Partners Investment Group’s Adaptimmune Therapeutics ADAP Stock Holding History

Chicago Partners Investment Group’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-12,265
Closed -$38K – 565
2021
Q4 		$38K Buy
+12,265
New +$55.8K ﹤0.01% 562
2021
Q1 		– Sell
-24,870
Closed -$139K – 520
2020
Q4 		$139K Buy
24,870
+14,178
+133% +$77K 0.01% 449
2020
Q3 		$56K Buy
+10,692
New +$93.6K 0.01% 401

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Chicago Partners Investment Group's ADAP Position: Q1 2022 in Review

Chicago Partners Investment Group sold out of Adaptimmune Therapeutics (ADAP) in Q1 2022, closing a stake of 12,265 shares — an estimated $38K sold.

Chicago Partners Investment Group first reported a position in ADAP in Q3 2020 and held it in 3 quarters. The position peaked at $139K in Q4 2020. 80 funds tracked by Wall St. Rank hold ADAP as of Q1 2022.

  • Chicago Partners Investment Group reported no remaining Adaptimmune Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Chicago Partners Investment Group sold 12,265 Adaptimmune Therapeutics shares in Q1 2022, an estimated $38K.
  • Chicago Partners Investment Group first reported a position in Adaptimmune Therapeutics in Q3 2020 and held it in 3 quarters.
  • Chicago Partners Investment Group's Adaptimmune Therapeutics position peaked at $139K in Q4 2020.
  • 80 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2022.

Based on Chicago Partners Investment Group's 13F filing for Q1 2022, filed 20 May 2022.